Experimental Hematology
Volume 38, Issue 9 , Pages 773-781 , September 2010

Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model

  • Juwon Park

      Affiliations

    • Cancer Research Institute, Seoul, Republic of Korea
    • ,
  • Kyung Im Kim

      Affiliations

    • College of Pharmacy, Seoul National University, Seoul, Republic of Korea
    • ,
  • Youngil Koh

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Nam-Hee Won

      Affiliations

    • Department of Pathology, Korea University College of Medicine, Environmental Toxicogenomic and Proteomics Research Center, Korea University, Seoul, Republic of Korea
    • ,
  • Jung Mi Oh

      Affiliations

    • College of Pharmacy, Seoul National University, Seoul, Republic of Korea
    • ,
  • Dong Soon Lee

      Affiliations

    • Department of Clinical Pathology, Seoul National University Hospital, Seoul, Republic of Korea
    • ,
  • Byoung Kook Kim

      Affiliations

    • Cancer Research Institute, Seoul, Republic of Korea
    • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Kwang-Sung Ahn

      Affiliations

    • Department of Pathology, Korea University College of Medicine, Environmental Toxicogenomic and Proteomics Research Center, Korea University, Seoul, Republic of Korea
    • Drs. Yoon and Ahn contributed equally to this work.
    • ,
  • Sung-Soo Yoon

      Affiliations

    • Cancer Research Institute, Seoul, Republic of Korea
    • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
    • Drs. Yoon and Ahn contributed equally to this work.
    • Corresponding Author InformationOffprint requests to: Sung-Soo Yoon, M.D., Ph.D., Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehang-ro, Jongno-gu, Seoul 110-799, Korea

Received 8 November 2009 ,Revised 13 April 2010 ,Accepted 23 April 2010.

References 

  1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330–1340
  2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–172
  3. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172–183
  4. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res. 2001;61:2343–2355
  5. Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene. 2002;21:8541–8546
  6. Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta. 2001;1551:M11–M18
  7. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000;96:3195–3199
  8. Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol. 2002;9:303–307
  9. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276–283
  10. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190–2196
  11. Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet. 2002;139:30–33
  12. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690–698
  13. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004;64:672–677
  14. Dorsey JF, Cunnick JM, Lanehart R, et al. Interleukin-3 protects Bcr-Abl transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia. 2002;16:1589–1595

PII: S0301-472X(10)00155-4

doi: 10.1016/j.exphem.2010.04.012

Experimental Hematology
Volume 38, Issue 9 , Pages 773-781 , September 2010

Article Tools

* Image Usage & Resolution